Frank Torres, MD
Family Medicine · Harlingen, TXNPI 1972500551
Payments from drug & device makers
Across 121 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$602
- Lilly USA, LLC$298
- Amarin Pharma, Inc.$137
- Exact Sciences$102
- GSK$86
- Dexcom, Inc.$70
- plus $617 from 23 others
What the payments were for
- Food & beverage$1,88499%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $602 |
| Lilly USA, LLC | 27 | $298 |
| Amarin Pharma, Inc. | 2 | $137 |
| Exact Sciences | 5 | $102 |
| GSK | 4 | $86 |
| Dexcom, Inc. | 4 | $70 |
| Pfizer | 4 | $68 |
| Sanofi Pasteur Inc. | 3 | $46 |
| Nevro Corp. | 2 | $46 |
| Boehringer Ingelheim | 2 | $41 |
| AbbVie | 2 | $41 |
| AstraZeneca | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $26 |
| Intuitive Surgical | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,912 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 292 | $172,713 |
| OzempicSemaglutide | 110 | $144,557 |
| RybelsusSemaglutide | 71 | $83,229 |
| LinzessLinaclotide | 126 | $80,272 |
| FarxigaDapagliflozin Propanediol | 72 | $72,468 |
| JardianceEmpagliflozin | 76 | $58,434 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $54,657 |
| EliquisApixaban | 69 | $51,654 |
| JanuviaSitagliptin Phosphate | 49 | $42,308 |
| TrulicityDulaglutide | 37 | $37,598 |
| JentaduetoLinagliptin/Metformin Hcl | 55 | $32,680 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 17 | $26,977 |
| XareltoRivaroxaban | 41 | $26,808 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $20,615 |
| MyrbetriqMirabegron | 47 | $20,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Jentadueto, Synjardy Xr, Synjardy | $41 | $281,473454 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog Mix 70-30, Levemir | $602 | $264,757230 claims |
| AbbVieLinzess | $41 | $80,272126 claims |
| AstraZenecaFarxiga, Brilinta | $36 | $78,49586 claims |
| PfizerEliquis, Nurtec Odt | $68 | $69,23988 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $86 | $62,22195 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $298 | $56,01855 claims |
| Johnson & JohnsonXarelto | $26 | $26,80841 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $20,58147 claims |
| BayerKerendia | $14 | $6,71611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Harlingen
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.